New pharmacologic approaches to treating diabetic retinopathy

American Journal of Health-System Pharmacy

Volumn 64, Issue 17 SUPPL., 2007, Pages

  Ryan, Gina J ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Aldose reductase inhibitors; Antibodies; Diabetic retinopathy; Enzyme inhibitors; Lasers; Midostaurin; Quality of life; Ruboxistaurin; Steroids, cortico ; Toxicity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; BEVACIZUMAB; CORTICOSTEROID; EPALRESTAT; FIDARESTAT; MIDOSTAURIN; PEGAPTANIB; PLACEBO; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RANIRESTAT; RUBOXISTAURIN; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ABSENCE OF SIDE EFFECTS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONFERENCE PAPER; DIABETIC RETINOPATHY; DIARRHEA; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; LASER COAGULATION; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; VISUAL ACUITY; VOMITING; DRUG DELIVERY SYSTEM; ENZYMOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY; REVIEW;

DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 35349008113     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070332     Document Type: Conference Paper

References (41)

1. American Academy of Ophthalmology. Diabetic retinopathy preferred practice pattern. 2003. http://www.aao.org/education/library/ppp/upload/ Diabetic_Retinopathy.pdf (accessed 2007 Feb 22).
2. Maeshima K, Utsugi-Sutoh N, Otani T et al. Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy. Retina. 2004; 24:507-11.
3. Cuilla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003; 26:2653-64.
4. Joy SV, Scates AC, Bearilly S et al. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother. 2005; 39:1693-9.
5. Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr Drug Targets. 2005; 6:475-86.
6. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002; 288:2579-88.
7. Avignon A, Sultan A. PKC-B inhibition: a new therapeutic approach for diabetic complications? Diabetes Metab. 2006; 32:205-13.
8. Krans HM. Recent clinical experience with aldose reductase inhibitors. J Diabetes Complications. 1992; 6:39-44.
9. Ryder S, Sarokhan B, Shand DG. Human safety profile of tolrestat: an aldose reductase inhibitor. Drug Dev Res. 1987; 11:131-43.
10. van Gerven JM, Boot JP, Lemkes HH et al. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc Ophthalmol. 1994; 87:355-65.
11. Hotta N, Akanuma Y, Kawamori R et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006; 29:1538-44.
12. Hotta N, Toyota T, Matsuoka K et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001; 24:1776-82.
13. Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2006; 29:68-72.
14. Fabbro D, Ruetz S, Bodis S et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000; 15:17-28.
15. PKC412, daunorubicin, and cytarabine in treating patients with newly diagnosed acute myeloid leukemia. http://www.clinicaltrials.gov/ct/show/ NCT00093600?order=1 (accessed 2007 Mar 2).
16. Phase II PKC412 in aggressive systemic mastocytosis and mast cell leukemia. http://www.clinicaltrials.gov/ct/show/NCT00233454?order=2 (accessed 2007 Mar 2).
17. Campochiaro PA, C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004; 45:922-31.
18. PKC-DRS2 Group, Aiello LP, Davis MD et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006; 113:2221-30.
19. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005; 54:2188-97.
20. Effect of ruboxistaurin on clinically significant macular edema. http://www.clinicaltrials.gov/ct/show/NCT00133952?order=1 (accessed 2007 Feb 23).
21. Reduction in the occurrence of center-threatening diabetic macular edema. http://www.clinicaltrials.gov/ct/show/NCT00090519?order=2 (accessed 2007 Feb 23).
22. Antoszyk AN, Gottlieb JL, Machemer R et al. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1993; 231:34-40.
23. Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology. 1986; 119:1768-75.
24. Matsuda S, Gomi F, Oshima Y et al. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci. 2005; 46:1062-68.
25. Stokes CL, Weisz PB, Williams SK et al. Inhibition of microvascular endothelial cell migration by beta-cyclodextrin tetradecasulfate and hydrocortisone. Microvasc Res. 1990; 40:279-84.
26. Gillies MC, Sutter FK, Simpson JM et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006; 113:1533-8.
27. Patelli F, Fasolino G, Radice P et al. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina. 2005; 25:840-5.
28. Avastin package insert. South San Francisco, CA: Genentech, Inc; October 2006.
29. Macugen package insert. New York, NY: Pfizer Inc; July 2006.
30. Lucentis package insert. South San Francisco, CA: Genentech, Inc; June 2006.
31. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006; 113:1695.
32. Jorge R, Costa RA, Calucci D et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006; 26:1006-13.
33. Haritoglou C, Kook D, Neubauer A et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006; 26:999-1005.
34. Spaide RF, Risher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006; 26:275-8.
35. Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005; 112:1035-47.
36. Cunningham ET Jr, Adamis AP, Altaweel M et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005; 112:1747-57.
37. Nguyen QD, Tatlipinar S, Shah SM et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006; 142:961-9.
38. Efficacy study of Lucentis in the treatment of diabetic macular edema. http://www.clinicaltrials.gov/ct/show/NCT00387582?order=4. (accessed 2007 Mar 5).
39. Study comparing two doses of ranibizumab in the treatment of clinically significant diabetic macular edema. http://www.clinicaltrials.gov/ct/show/ NCT00440609?order=7. (accessed 2007 Mar 5).
40. RESOLVE: safety and efficacy of ranibizumab in diabetic macular edema with center involvement. http://www.clinicaltrials.gov/ct/show/NCT00284050? order=13 (accessed 2007 Mar 5).
41. The READ-2 (ranibizumab for edema of the macula in diabetes) study. http://www.clinicaltrials.gov/ct/show/NCT00407381?order=14. (accessed 2007 Mar 5).